Get started
Finer Market Points: ASX Top 10 Momentum Stocks: 9 Aug 2024ASX:ATX NYSE:AME ASX:APX ASX:RIM ASX:IXU AMEX:TTT EURONEXT:MAU GETTEX:AQC SP:SPX ASX:LRV Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on our Launch Pad list. The Launch Pad List is published weekly on Fridays. Today's ASX's Top 10 Quarterly Momentum Stocks are: Amplia Therapeutics Limited (ATX) Alto Metals Limited (AME) Appen Limited (APX) Rimfire Pacific Mining Limited (RIM) IXUP Limited (IXU) Titomic Limited (TTT) Magnetic Resources NL (MAU) Australian Pacific Coal Limited (AQC) Spenda Limited (SPX) Larvotto Resources Limited (LRV)
ASX:RIM
by ch886
Telix Pharmaceuticals: A Game-Changer in Brain Cancer ImagingTelix Pharmaceuticals Limited (ASX: TLX) has announced a significant development in its journey towards transforming brain cancer diagnostics. The company has opened an Expanded Access Program (EAP) in the United States for TLX101-CDx (Pixclara™1, 18F-floretyrosine or 18F-FET), an investigational PET agent for imaging progressive or recurrent glioma. This move comes after receiving the green light from the U.S. Food and Drug Administration (FDA), marking a major milestone for Telix in addressing the unmet medical needs in glioma imaging. The Need for Advanced Glioma Imaging Glioma is the most common and aggressive form of primary brain cancer, notoriously difficult to diagnose and monitor accurately with conventional MRI. Traditional MRI has limitations, including lack of biological specificity, dependency on blood-brain barrier disruption, and difficulty in differentiating between tumor progression and treatment-related changes. These challenges underscore the critical need for more precise imaging techniques. Dr. Patrick Wen, a renowned neurologist from Harvard Medical School and Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, emphasized the potential of TLX101-CDx to revolutionize glioma imaging. "Amino acid PET imaging of the brain is increasingly used to supplement conventional imaging by MRI. TLX101-CDx (FET-PET) shows potential to provide a more rapid and conclusive diagnosis, inform treatment decisions, and deliver a new standard for the management of gliomas in the U.S.," he said. Expanded Access Program and Future Prospects The FDA's EAP, also known as 'compassionate use,' allows patients with serious or life-threatening conditions to access investigational products outside of clinical trials. This initiative by Telix ensures that glioma patients in the U.S. can benefit from TLX101-CDx even before its formal approval. David N. Cade, MD, Telix's Chief Medical Officer, highlighted the importance of this program, stating, "The opening of this expanded access program will enable us to provide continued access to this investigational agent, where there is significant unmet medical need in the U.S." Telix plans to file its New Drug Application (NDA) for TLX101-CDx with the FDA during Q3 2024, aiming to make this advanced imaging agent commercially available in the U.S. for both adult and pediatric patients. Financial Growth and Market Position Telix Pharmaceuticals has also revised its full-year revenue forecast upwards, following a robust second quarter. The company now expects revenue to fall within the range of $US490 million to $US510 million, approximately 10% higher than previous guidance. This surge in revenue is primarily driven by higher sales of its prostate cancer imaging product, Illuccix, in the U.S. Telix's shares have seen a remarkable rise, hitting a fresh record high of $20.76 before stabilizing around $19.81 on Monday Market trading. The company's CEO, Christian Behrenbruch, attributed this growth to "excellent quarterly growth in both revenue and dose volume sales of Illuccix." Despite the impressive financial performance, Telix continues to invest heavily in research and development, with plans to increase R&D spending by 40% to 50% compared to the prior year. This investment is crucial for the continued development of its innovative diagnostic solutions, including TLX101-CDx and other therapies like Zircaix for diagnosing kidney cancers. The Road Ahead Telix Pharmaceuticals is poised to make significant strides in the field of cancer diagnostics. The launch of the EAP for TLX101-CDx in the U.S. and the forthcoming NDA submission highlight the company's commitment to addressing critical gaps in glioma imaging. With its innovative products and strong financial performance, Telix is well-positioned to deliver robust growth and create substantial value for its shareholders. As the demand for advanced diagnostic solutions continues to rise, Telix's pioneering efforts in developing targeted imaging agents could set new standards in cancer care, offering hope and improved outcomes for patients worldwide. Conclusion Telix Pharmaceuticals' recent advancements and strategic initiatives underscore its potential to become a leader in the cancer diagnostics market. By addressing the critical needs in glioma imaging and leveraging its robust product pipeline, Telix ( ASX:TLX ) is on a path to achieve significant growth and impact the lives of countless patients battling cancer.
ASX:TLXLong
by DEXWireNews
LTR (ASX) chart resembles AmazonI've been looking at US stocks lately and going through the Ideas on Aussie stocks. I saw LTR and immediately thought of Amazon. There seems to be a common wave structure. The wave count technically is not Elliott Waves because: - Wave 4 on both charts enter the territory of Wave 2 - Wave 4 goes below Wave 3 on LTR. However, if you look at the general form of both charts, they are quite similar. If LTR behaves in a similar manner, then there could be quite an uptrend ahead.
ASX:LTRLong
by AuroraCharts
WR1.ASX Winsome Resources Trend Cloud Study.Winsome Resources has been Bashed Down with all the Lithium miners of the Last Year or more. Just as High Inflation is the cure for High Inflation, I surmise the same could be true for these Miners - as they are forced to shut down certain operations, thereby decreasing supply. They also become Targets for Takeovers and MA's. As my Chart depicts, I also was caught by many Bull Traps, and I am in a Loss Scenario. However, I am now seeing a potential reversal on the Trend Cloud and IMACD. Adding to my position remains very Risky and is not a recommended policy However if one got in near the recent lows & you are profitable - your Risk will be lower. As my Chart depicts, I Diarise as much information as possible using the Call-Out Tool and Price Range % to assist with my decisions. As always, please get a few outside Expert's Advice before taking Trade or Investment decisions. Should you appreciate my Chart Studies, Smash That Rocket Boost Button. It's Just a Click away. Regards Graham.
ASX:WR1Long
by hitchcoxg
3
Finer Market Points: ASX Top 10 Momentum Stocks: 25 Jul 2024NYSE:WTM ASX:QHL AMEX:TTT GETTEX:SKS ASX:ACW FWB:AL3 NYSE:SPR GETTEX:CYL ASX:EZZ ASX:RIM Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on our Launch Pad list. The Launch Pad List is published weekly on Fridays. Today's ASX's Top 10 Quarterly Momentum Stocks are: Waratah Minerals Limited (WTM) Quickstep Holdings Limited (QHL) Titomic Limited (TTT) SKS Technologies Group Limited (SKS) Actinogen Medical Limited (ACW) AML3D Limited (AL3) Spartan Resources Limited (SPR) Catalyst Metals Limited (CYL) EZZ Life Science Holdings Limited (EZZ) Rimfire Pacific Mining Limited (RIM)
ASX:SPR
by ch886
Simple technicals, Northern Star Resources - NST (ASX)Northern Star Resources - NST (ASX) In a long term bullish move, and medium term pullback with a recovery bounce off the 200-day moving average. We are starting to see a possible convergence on the medium-term MACD, which could lead to a recovery in the medium term, if buying continues. Full report details for members at marketmonkey.com.au Please feel free to request more Blue Chip technicals via hello@marketmonkey.com.au 🙈
ASX:NSTLong
by Market_Monkey_AU
Aristocrat Leisure - is price over extended?#ASX #ALL - Aristocrat Leisure Examining #ALL for July, the strength of buying remains moderate to strong, which is continuing to push the price higher towards the end of July. Currently on directional indicators in the Blue Chip stock analysis report (marketmonkey.com.au), the price is over extended for a second month. This over-exuberant buying tends to decline into the third month, when prices often weaken. No convergence as yet with the short-term moving averages, so price is likely to remain bullish in the very short term. Please feel free to request ASX stock analysis via hello@marketmonkey.com.au 🙈
ASX:ALL
by Market_Monkey_AU
AudinateBig watch on ASX:AD8 on a pretty strong support level. Could make a case for a triple bottom already, but I'm looking for a stronger touch. Kumo twist. Sideways consolidation on the daily. Coming up to testing the top of the cloud as support on the weekly. Don't mind the idea of buying here or DCA'ing for a period of time. Really interested to see what the price action will be like heading into 'Earnings & Revenue'. Of particular interest will be any progress made in the video space that has been much hyped. I haven't kept up enough with the news or the outlook to know when there is an expectation of revenue growth from this area.
ASX:AD8
by Swick15
Finer Market Points: ASX Top 10 Momentum Stocks: 18 Jul 2024ASX:I88 AMEX:TTT XETR:DGR NYSE:WTM GETTEX:SKS ASX:QHL GETTEX:CYL ASX:ACW ASX:EZZ FWB:AL3 Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on our Launch Pad list. The Launch Pad List is published weekly on Fridays. Today's ASX's Top 10 Quarterly Momentum Stocks are: Infinity Resources (I88) Titomic Limited (TTT) DGR Global Limited (DGR) Waratah Minerals Limited (WTM) SKS Technologies Group Limited (SKS) Quickstep Holdings Limited (QHL) Catalyst Metals Limited (CYL) Actinogen Medical Limited (ACW) EZZ Life Science Holdings Limited (EZZ) AML3D Limited (AL3)
ASX:TTT
by ch886